Skip to main content
Signal8

Enlivex Ltd. (ENLV) Form 6-K — Nov 18, 2026

$ENLVForm 6-KFiled Nov 18, 2026, 8:01 AM ET0001213900-26-121615Original filing

Enlivex announced that the independent DSMB completed an interim safety review of 85 patients in its Phase IIb knee osteoarthritis trial and confirmed Allocetra's safety profile allows enrollment to continue as planned. The randomized, double-blind, placebo-controlled trial (NCT07580716) plans to enroll approximately 182 patients across the US, Denmark and Poland, testing three intra-articular Allocetra injections in patients 64 and older with moderate-to-severe knee osteoarthritis. The DSMB clearance is a modest de-risking step; efficacy endpoints (pain and physical function at three and six months) remain the key catalyst, with topline data still pending.

Key figures

Countries
["United States","Denmark","Poland"]
Trial identifier
NCT07580716
Patients reviewed
85
Planned enrollment
182
Injections per patient
3

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    Enlivex Ltd. (ENLV) Form 6-K — Nov 18, 2026: AI Analysis | Signal8